SilverbergJI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017; 35(3):283–289; doi: 10.1016/j.det.2017.02.002
2.
WollenbergA, KinbergerM, ArentsB, et al.European guideline (EuroGuiDerm) on atopic eczema: Part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022; 36(9):1409–1431; doi: 10.1111/jdv.18345
3.
KleinSL, FlanaganKL. Sex differences in immune response. Nat Rev Immunol. 2016; 16(10):626–638; doi: 10.1038/nri.2016.90
4.
PaganA, DavidE, UngarB, et al.Dupilumab Improves Clinical Scores in Children and Adolescent with Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study. J Allergy Clin Immunol Pract. 2022; 10(9):2378–2385; doi: 10.1016/j.jaip.2022.06.014
5.
HallingAS, LoftN, SilverbergJI, et al.Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J Am Acad Dermatol., 2021; 84(1):139–147; doi: 10.1016/j.jaad.2020.08.051